Document is current
Any future updates will be listed below
-
Authors
Duplaquet, Leslie https://orcid.org/0000-0002-6544-0432
Li, Yixiang
Booker, Matthew A.
Xie, Yingtian
Olsen, Sarah Naomi https://orcid.org/0000-0002-9136-0778
Patel, Radhika A.
Hong, Deli
Hatton, Charlie https://orcid.org/0000-0001-9903-4291
Denize, Thomas
Walton, Emily https://orcid.org/0000-0003-2117-5988
Laimon, Yasmin N. https://orcid.org/0000-0003-0848-9843
Li, Rong https://orcid.org/0009-0000-1046-9580
Jiang, Yijia
Bronson, Roderick T.
Southard, Jackson
Li, Shuqiang https://orcid.org/0000-0001-9106-6141
Signoretti, Sabina https://orcid.org/0000-0002-5000-9105
Qiu, Xintao https://orcid.org/0000-0002-8560-7017
Cejas, Paloma https://orcid.org/0000-0002-2090-7748
Armstrong, Scott A. https://orcid.org/0000-0002-9099-4728
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Tolstorukov, Michael Y.
Haffner, Michael C.
Oser, Matthew G. https://orcid.org/0000-0003-2047-0969
-
Funding
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (CI-101-19)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA222657)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA269990)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R50CA251956)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA176745)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA066996)
Kaplan Family Fund
- License Information
-
More Information
Article History
Received: 26 July 2022
Accepted: 19 July 2023
First Online: 17 August 2023
Competing interests
: M.G.O. has (currently or previously) sponsored research agreements with Takeda, Eli Lilly, Novartis, Circle Pharma and Bristol Myers Squibb, and is a consultant for Daiichi Sankyo and Ananke Therapeutics. None of these sponsored research agreements was used to fund this work. S.A.A. has been a consultant and/or shareholder for Neomorph Inc, Imago Biosciences, Cyteir Therapeutics, C4 Therapeutics, Nimbus Therapeutics and Accent Therapeutics. S.A.A. has received research support from Janssen and Syndax. S.A.A. is named as an inventor on a patent application related to MENIN inhibition WO/2017/132398A1. The remaining authors declare no competing interests.
